Presenting the most comprehensive proteomic map of systemic lupus erythematosus to date! doi.org/10.1172/jci.... Leung et al. @imperialcollegeldn.bsky.social report potential therapeutic targets, biomarkers & autoantibody-linked proteomic signatures in SLE, providing a basis for precision medicine

Delighted to share this collaborative work evaluating phenotypes and outcomes of patients with #lupus meeting indication for #PrimaryAldosteronism testing More research is needed journals.sagepub.com/doi/10.1177/... @monashuniversity.bsky.social @hudsonresearch.bsky.social

Clinical phenotypes and disease outcomes of patients with systemic lupus erythematosus meeting indication for primary aldosteronism testing - Matthew Wong, Muhammad Akram, Joanna R. Kent, Peter J. Ful...

Background Hypertension is prevalent and contributes significantly to cardiovascular risk in patients with systemic lupus erythematosus (SLE). Primary aldostero...

journals.sagepub.com

The UKKA Glomerulonephritis SIG medicines workstream is inviting healthcare professionals working in secondary care to complete a short survey on the use of obinutuzumab for lupus nephritis and other renal indications. ⏱️ Approx. 5 minutes to complete 📝 Complete now: https://ow.ly/VIrJ50Zv4qj

✨ New this week in Arthritis Care & Research ✨ Employment trajectories of patients with SLE doi.org/10.1002/acr.... Monitoring RA disease activity using wearable biosensors and PRO data doi.org/10.1002/acr.... ↓

📣 Delighted to be speaking at the 15th Meeting of the Lupus Academy in Bratislava 🇸🇰 I’ll be taking part in the opening debate: ⚖️ Early biologic treatment in systemic lupus: necessary or overemphasized? 📅 3–5 September 2026 💻 In-person and virtual 🔗 lupus-academy.org/registrations/

Data from 1,806 patients w/ SLE over median 18 years of follow-up showed a lack of transition between employment states. 84% who were initially receiving disability benefits remained on disability benefits, with neuropsychiatric & renal damage as key disability drivers AC&R doi.org/10.1002/acr....

Among 784,091 pts in UK acute MI registry, 715 (0.1%) had SLE. SLE pts were younger & more female. SLE w/ MI had signif higher adjusted all-cause mortality from 30 days (HR 1.62) to 5 years (HR 1.84), despite age & having less traditional cardiovascular comorbidities academic.oup.com/rheumatology...

Assessing the mortality burden after acute myocardial infarction in systemic lupus erythematosus: insights from the MINAP Registry

AbstractObjectives. Acute myocardial infarction (AMI) is a leading cause of mortality globally. Although SLE is known to increase the risk of AMI, its impa

academic.oup.com

Rates of progression from #DiscoidLupusErythematosus to #SystemicLupusErythematosus increased over time, from 14.4% at year 1, to 16.7% at year 2, and to 20.9% at year 5. https://www.dermatologyadvisor.com/news/1-in-5-children-discoid-lupus-erythematosus-progress-sle-within-5-years/

1 in 5 Children With Discoid Lupus Erythematosus Progress to SLE Within 5 Years

At 5 years, 20.9% of children and adolescents with DLE progressed to SLE, and several risk factors for progression were identified.

dermatologyadvisor.com

Interesting discussions on Substack about their new tool checking for AI generated texts 🤖

☀️ Our #lupus community knows that sun protection is a year-round priority. This #UVAwarenessMonth, wide-brimmed hats, SPF, long sleeves, and seeking shade all make a difference. Learn how to protect yourself from UV exposure: buff.ly/VoxRJVf

Excited to share our new paper in @cellpressblue.bsky.social. We show that #lupus shifts neutrophils away from bactericidal NETosis and toward a less protective vital NET release. Huge thanks to Eden, our trainees, and collaborators! @utkmicrobiology.bsky.social www.cell.com/cell-press-b...

TLR7/9 and type I interferon signaling reprogram neutrophil NET responses and impair antibacterial defense in systemic lupus erythematosus

TenBarge et al. show that lupus-associated TLR7/9 and type I interferon signaling reprogram neutrophil NET responses during Staphylococcus aureus infection. This shifts neutrophils away from LDHB-depe...

cell.com

#KDOQI US Commentary on the @kdigo.org 2024 Clinical Practice Guideline for the Management of Lupus Nephritis bit.ly/KDOQI26Lupus (FREE) @saynanorouzi.bsky.social @nkf-professionals.bsky.social

Which children with persistent aPL antibodies and hematologic manifestations are at greatest risk of developing APS and/or SLE? In a prospective cohort with up to 29 years of follow-up, baseline Evans syndrome was the strongest predictor of progression.

It’s World Brain Day! 🧠 A great day to learn some fascinating facts about this powerful, mysterious and amazing organ. Did you know that information in the brain can travel at speeds of up to 350 miles/hour (563 km/h)? 🤯🏎️ #WBD2026

On World Brain day, we're recognising the importance of brain health and the vital role research plays in improving people's lives. Globally, more than 3.4 billion people live with neurological conditions, yet millions lack access to necessary care. 1/2🧵

Today marks World Brain Day, we've got a small selection our titles on the topic displayed here, but check out the library catalogue for the full selection! Don't forget we can request books from other libraries if they're not available with us! #brain #library #interlibraryloans

How faithful is Nolan’s The Odyssey to Homer? 🎬 Professor Armand D’Angour explores how the film turns an ancient epic into a modern spectacle. Warning - the article contains spoilers! ⬇️ https://www.ox.ac.uk/news/2026-07-20-expert-comment-is-christopher-nolans-odyssey-faithful-to-homer

🧠 Tomorrow is World Brain Day 🩷🩷 #WBD2026

Challenges persist in defining & assessing renal response to therapy in lupus nephritis. Review examines current limitations of renal outcome definitions & provides a perspective toward uniform definitions of response in LN trials, renal flare/relapse, & refractory disease doi.org/10.1002/acr2...

Essential reading for clinicians managing lupus. BSR has published the 2026 guideline for management of children, young people and adults with SLE. Read open access: oxford.ly/4bQMnxN #Rheumatology #Rheumsky

Excited to share our latest #lupus research in RMDOpen By profiling >1,600 IgA autoantibodies -understudied part of the immune system in lupus- we identified distinct immune signatures associated with lupus phenotypes & uncovered new biomarker candidates rmdopen.bmj.com/content/12/3...

Serum IgA autoantibody profiling in systemic lupus erythematosus reveals associations with disease phenotypes

Background Knowledge of the role of IgA isotype autoantibodies in systemic lupus erythematosus (SLE) is lacking. We aimed to explore associations between serum IgA autoantibody profiles and SLE clinic...

rmdopen.bmj.com

Happy to share a little review published in Med (Cell Press) on what myself and @sarahjones think is coming in #lupus. A lot of pathway validation via human trials is on its way to us www.sciencedirect.com/science/arti...

📄 The UKKA endorses the updated British Society for Rheumatology guideline for systemic lupus erythematosus (SLE), including updated recommendations for lupus nephritis & advances in diagnosis, monitoring & treatment. 📖 Executive summary: https://doi.org/10.1093/rheumatology/keag224 #KidneyCare

Research Article Differences in Self-Reported Medication Nonadherence and Its Drivers in Young Adults Versus Older Adults With Systemic Lupus Erythematosus 📖 www.jrheum.org/cgi/content/... @dukemedschool.bsky.social #MedicationAdherence #YoungAdult #SLE

New @upenn.edu research sheds further light on molecular mechanisms that lead to #lupus and other autoimmune diseases most common in women. Read the research: buff.ly/5c2Kl5e

#Lupus

Science Seminars@scienceseminars.org · last mo.

Science Seminar 9 July 2pm with Dr. Joel Babdor (University of Pennsylvania): Microbiome-derived metabolites regulate the interferon immune tone. Please register on Eventbrite: shorturl.at/Lxfru @upenn.edu @pennmedicine.bsky.social @cumedicengage.bsky.social

Understanding clinical trial phases is one of the first steps to feeling confident about participation. Check out our breakdown of each phase and learn how your involvement could help move #lupus treatment forward. 🔗 Find a clinical trial near you: buff.ly/zDQKa96 #Rheumsky #Medsky

The hot weather is exhausting! ☀️

The "Lupus in Black: Science, Stories & Systems of Recovery & Flourishing” conference is taking place on 9th July from 9:00am - 5:30pm. Attend online or in person at Deane Lecture Theatre, University of Greater Manchester, Bolton, BL3 5AB. 🔗Interested? Sign up by 5th July: https://bit.ly/4vNcfmg

Excited to share our latest work ! Here, we identified the lectin CLEC7A as a sensor of aberrant IgG glycosylation, signaling through SYK to drive podocyte injury. This study is part of a broader effort in our group to understand immune-podocyte crosstalk in lupus nephritis.

ACR Journals@acr-journals.bsky.social · last mo.

New insights in lupus nephritis show abnormal IgG glycosylation triggers podocyte injury via CLEC7A-SYK signaling. Blocking this pathway preserved podocyte function, uncovering a potential novel therapeutic strategy for LN Arthritis & Rheumatology doi.org/10.1002/art....